Candel Therapeutics (CADL) to Release Earnings on Thursday

Candel Therapeutics (NASDAQ:CADL) is anticipated to release its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Candel Therapeutics to post earnings of ($0.24) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 13, 2026 at 4:00 PM ET.

Candel Therapeutics Stock Performance

NASDAQ:CADL opened at $4.95 on Thursday. The stock’s 50-day moving average is $5.70 and its 200-day moving average is $5.47. Candel Therapeutics has a 1-year low of $4.25 and a 1-year high of $9.08. The company has a current ratio of 8.25, a quick ratio of 8.25 and a debt-to-equity ratio of 0.01. The stock has a market cap of $271.76 million, a P/E ratio of -8.68 and a beta of -0.91.

Insider Transactions at Candel Therapeutics

In other Candel Therapeutics news, Director Paul B. Manning acquired 550,458 shares of the stock in a transaction on Monday, February 23rd. The shares were purchased at an average price of $5.45 per share, for a total transaction of $2,999,996.10. Following the completion of the acquisition, the director owned 2,763,527 shares in the company, valued at approximately $15,061,222.15. This represents a 24.87% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders own 16.60% of the company’s stock.

Institutional Investors Weigh In On Candel Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its holdings in shares of Candel Therapeutics by 12.3% in the 3rd quarter. Vanguard Group Inc. now owns 2,007,112 shares of the company’s stock worth $10,236,000 after acquiring an additional 219,563 shares during the last quarter. Geode Capital Management LLC increased its holdings in Candel Therapeutics by 31.5% during the 2nd quarter. Geode Capital Management LLC now owns 903,970 shares of the company’s stock worth $4,575,000 after purchasing an additional 216,509 shares in the last quarter. Millennium Management LLC bought a new stake in Candel Therapeutics during the 3rd quarter worth approximately $697,000. State Street Corp increased its holdings in Candel Therapeutics by 15.0% during the 4th quarter. State Street Corp now owns 792,218 shares of the company’s stock worth $4,476,000 after purchasing an additional 103,452 shares in the last quarter. Finally, Lido Advisors LLC purchased a new stake in shares of Candel Therapeutics in the third quarter worth approximately $307,000. 13.93% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Candel Therapeutics in a report on Wednesday, January 21st. Stephens restated an “overweight” rating and set a $15.00 price objective on shares of Candel Therapeutics in a research report on Monday, December 8th. Zacks Research cut Candel Therapeutics from a “hold” rating to a “strong sell” rating in a report on Monday, January 19th. Wall Street Zen downgraded shares of Candel Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, Citigroup lowered their price target on shares of Candel Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a report on Friday, November 14th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $17.00.

About Candel Therapeutics

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.